Abstract
Three-dimensional quantitative structure-activity relationship (3-D QSAR) was performed using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques in order to understand the carbonic anhydrase inhibition activity. A large number of 25 structurally and functionally diverse series of aromatic heterocyclic sulfonamides carbonic anhydrase (CA, EC 4.2.1.1) inhibitors, such as hCA II were chosen for the study. Based on the alignment generated by docking conformations, a highly predictive comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models were developed with q2 value of 0.532 and 0.486 & r2 value of 0.978 and 0.952, respectively. Further, mapping of contours onto the active site validated each other in terms of residues involved with reference to respective contours. This integrated molecular docking based alignment followed by 3D-QSAR studies should provide further insights to support structure based design of human carbonic anhydrase II inhibitors with improved activity profile.
Keywords: 3D-QSAR, CoMFA, CoMSIA, Docking, Carbonic anhydrase inhibitors, hCA II
Letters in Drug Design & Discovery
Title:3D-QSAR Study of Some Heterocyclic Sulfonamide Analogs as hCAII Inhibitors
Volume: 9 Issue: 6
Author(s): Saurabh M. Verma, Arabinda Saha, Rahul Mishra and Kalyan K. Sethi
Affiliation:
Keywords: 3D-QSAR, CoMFA, CoMSIA, Docking, Carbonic anhydrase inhibitors, hCA II
Abstract: Three-dimensional quantitative structure-activity relationship (3-D QSAR) was performed using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques in order to understand the carbonic anhydrase inhibition activity. A large number of 25 structurally and functionally diverse series of aromatic heterocyclic sulfonamides carbonic anhydrase (CA, EC 4.2.1.1) inhibitors, such as hCA II were chosen for the study. Based on the alignment generated by docking conformations, a highly predictive comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models were developed with q2 value of 0.532 and 0.486 & r2 value of 0.978 and 0.952, respectively. Further, mapping of contours onto the active site validated each other in terms of residues involved with reference to respective contours. This integrated molecular docking based alignment followed by 3D-QSAR studies should provide further insights to support structure based design of human carbonic anhydrase II inhibitors with improved activity profile.
Export Options
About this article
Cite this article as:
M. Verma Saurabh, Saha Arabinda, Mishra Rahul and K. Sethi Kalyan, 3D-QSAR Study of Some Heterocyclic Sulfonamide Analogs as hCAII Inhibitors, Letters in Drug Design & Discovery 2012; 9 (6) . https://dx.doi.org/10.2174/157018012800673001
DOI https://dx.doi.org/10.2174/157018012800673001 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies
Current Pharmaceutical Design Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Serum Thiol-Disulphide Levels in Epileptic Pediatric Patients
Combinatorial Chemistry & High Throughput Screening Synthesis, Anticonvulsant Evaluation of 2,3,4,5-Tetrahydro-7-alkoxy-1H-2-benzazepin-1-ones
Letters in Drug Design & Discovery Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research 5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design